Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

unknown1
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

unknown133%
completed133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
unknown

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

NCT04710056
terminatedphase_2

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

NCT05088460
completedphase_1

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

NCT03530514

Clinical Trials (3)

Showing 3 of 3 trials
NCT04710056

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

Unknown
NCT05088460Phase 2

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Terminated
NCT03530514Phase 1

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3